How The UK Regulatory System Would Work In A No-Deal Brexit – Part 2
Executive Summary
In this second article on the regulations published by the government on how the UK would regulate medicines in a “no-deal” Brexit scenario, we look at what is being proposed for areas such as pediatric investigation plans, orphan medicines, pharmacovigilance, parallel trade, generics approvals, and good manufacturing and distribution practices.
You may also be interested in...
MHRA Reinforces Brexit Road-Map, Indian Firms Expect Tough Transition
The MHRA highlighted at a recent conference in India the key changes that await pharma in the event of a no-deal Brexit, and the agency’s general readiness in that scenario, including putting in place its own IT systems such as a UK national replacement for the EudraGMDP.
UK Offers Pharma Firms Ferry Tickets To Avoid No-Deal Brexit Supply Disruptions
The UK health department says it has purchased ferry tickets that pharmaceutical companies can buy in order to transport their medicines and other product using alternative shipping routes between EU and UK ports in the event of a no-deal Brexit. It has also updated companies on how they can access additional warehousing space for medicine stockpiles.
Brexit Won't Impair Pharmacovigilence 'Fundamentals' – DIA Panel
MHRA pharmacovigilance leader says global safety efforts will not lose UK expertise.